Inflammasomes are multiprotein complexes that sense pathogen-associated and danger-associated molecular patterns and induce inflammation in cells. The NALP3 inflammasome is tightly regulated by recently discovered control mechanisms, but other modulators still remain to be characterized. NLR family CARD-containing 3 (NLRC3) protein, a caspase recruitment domain (CARD)–containing member of the nucleotide oligomerization domain–like receptor (NLR) family, was found to down-regulate the NF-κB pathway and stimulator of interferon genes (STING)–dependent cytokine secretion. However, the effect of NLRC3 on the NALP3 inflammasome or other inflammasomes is still unknown. We hypothesized that NLRC3 might inhibit NALP3 inflammasome complex assembly. Toward this end, we tested whether NLRC3 overexpression or knockdown influences NALP3 activity in human monocyte and HEK293FT cells when the complex is ectopically reconstituted. We found that NLRC3 indeed decreases NALP3-induced IL-1β maturation and secretion, pro-caspase-1 cleavage, and speck formation by apoptosis-associated speck-like protein containing a CARD (ASC) protein in response to NALP3 activators. We also show that endogenous NLRC3 interacts with both ASC and pro-caspase-1 but not with NALP3, disrupts ASC speck formation through its CARD, and impairs the ASC and pro-caspase-1 interaction. Moreover, the NLRC3 CARD alone could dampen IL-1β secretion and ASC speck formation induced by NALP3 mutants associated with autoinflammatory diseases. In conclusion, we show here that, besides its role in the inhibition of the NF-κB pathway, NLRC3 interferes with the assembly and activity of the NALP3 inflammasome complex by competing with ASC for pro-caspase-1 binding.

Inflammasomes are multiprotein complexes responsible for the sensing of pathogen-associated molecular patterns and danger-associated molecular patterns and the induction of inflammation (1). Different types of inflammasomes have been identified, and most of them have in common the adaptor protein ASC, the effector pro-caspase-1, and the downstream inflammatory mediator cytokine pro-IL-1β (2). The assembly of the inflammasome is mediated by the homotypic interaction of ASC and pro-caspase-1 through their CARDs (3) and the formation of ASC foci called “specks” (4). This interaction results in the cleavage of pro-caspase-1 and the maturation and secretion of IL-1β (4). The NALP3 (also called NLRP3 or cryopyrin) inflammasome is specifically activated by ionophores such as ATP and nigericin (5), crystals such as monosodium urate (MSU) (6) and many others, whereas the NLRC4 (or IPAF) inflammasome is stimulated by Pseudomonas aeruginosa infection (7). A two-step process is required to promote the secretion of IL-1β by the NALP3 inflammasome: the induction of the NFκB pathway through Toll-like receptors (called the “priming step”) (8) and the complex assembly (called the “activation step”) mediated by potassium efflux (9, 10), lysosomal rupture (11), and reactive oxygen species production (12).

Mutations in the NALP3 gene are associated with autoinflammatory syndromes known as cryopyrin-associated periodic syndromes (or CAPS) (13), and among these mutations, the NALP3 p.R260W, and p.D303N mutants enhance the ectopic assembly of ASC specks (14, 15) and result in an increase in pro-caspase-1 cleavage (14) and IL-1β secretion (16, 17). IL-1β blockers such as anakinra are used to treat CAPS (18, 19), and identification of novel inhibitors of the NALP3 inflammasome that act upstream of IL-1β, on the NALP3 mRNA level (20), on ASC oligomerization (21), or on caspase-1 inhibition (22), is presently ongoing, and these inhibitors may be used in therapy of autoinflammatory diseases in the future.

Although the most studied NOD-like receptor (NLR) family members belong to the pro-inflammatory group, more recently, NLR proteins with anti-inflammatory roles have been characterized. Especially the members of the NLRC subgroup, NLRC5, NLRX1, and NLRC3, were shown to be negative regulators of inflammation. NLRX1 inhibited the NFκB pathway by binding to the active IκB kinase in response to LPS stimulation.
NLRC3 inhibits NALP3 inflammasome-induced inflammation

(23, 24). Furthermore, increased IFN-β secretion was observed in immune cells from NLRC5 knock-out mice when stimulated with vesicular stomatitis virus or poly(I:C) (24).

NLRC3, a less studied member of the NLR family, contains a C-terminal leucine-rich repeat (LRR) domain, a central NACHT domain and a N-terminal CARD (25). NLRC3 was shown to inhibit the NFκB pathway (25, 26) through the ubiquitination of TRAF6 (26). NLRC3 also inhibited stimulator of interferon genes–dependent IFN-β production (27) and IL-6 secretions in response to cytoplasmic DNA stimulation. NLRC3 altered cytokine secretion in HEK293FT cells (28).

Overexpression of NLRC3 inhibits NALP3-induced IL-1β secretion

Previous studies showed that overexpression of the inflammasome components was sufficient to induce activation of the complex and maturation and secretion of caspase-1 and IL-1β in a NALP3- and ASC-dependent manner. To assess whether NLRC3 has an effect on the activation of the complex, we ectopically expressed NALP3, ASC, pro-caspase-1, and pro-IL-1β in HEK293FT cells in the presence or the absence of NLRC3 and measured the resulting IL-1β secretion. Although negligible levels of IL-1β were secreted from ASC, pro-caspase-1 and pro-IL-1β co-transfected HEK293FT cells, co-expression of NALP3 with these proteins induced a dose-dependent increase in IL-1β secretion (Fig. 1A; 496 ± 42.7 pg/ml for 250 ng, 1400 ± 427.5 pg/ml for 500 ng, and 2903.7 ± 229.81 pg/ml for 1000 ng of NALP3 plasmid), thus confirming the specificity of the experimental setting. Interestingly, when NLRC3 was co-expressed with NALP3 and the other inflammasome-forming proteins, a significant reduction in IL-1β secretion was observed (Fig. 1B; 2903.7 ± 229.81 pg/ml for 1000 ng of NALP3 plasmid alone versus 1403.5 ± 48.11 pg/ml for 1000 ng of NLRC3 and 1000 ng of NALP3 plasmids, p = 0.0001). Moreover, the more NLRC3 was expressed, the higher decrease in IL-1β release that was obtained (2925.5 ± 151.2 pg/ml for 250 ng, 1949.3 ± 171.9 pg/ml for 500 ng, and 1403.5 ± 48.11 pg/ml for 1000 ng of NLRC3 plasmid co-transfected with 1000 ng of NALP3 plasmid). NLRC3 not only dampened NALP3-induced IL-1β secretion (Fig. 1, A and B) but also inhibited pro-IL-1β maturation (Fig. 1C) when ectopically expressed in HEK293FT cells.

To further confirm our results, we generated THP-1 stable lines that overexpressed the NLRC3 protein (named OvNLRC3) and confirmed its expression both at the mRNA (Fig. 1D) and the protein levels (Fig. 1E). Induction of the NALP3 inflammasome by stimulating stable THP-1 cells with nigericin (Fig. 1F) or MSU (Fig. 1G) triggered a significantly lower IL-1β release from THP-1 OvNLRC3 cells compared with their OvControl counterpart (3084.8 ± 64.1 pg/ml for OvNLRC3 versus 6385.7 ± 287.2 pg/ml for OvCont when treated with nigericin, p = 0.0039), suggesting that NLRC3 acts as an inhibitor of NALP3-induced IL-1β secretion in both cell types.

Knockdown of NLRC3 in THP-1 cells results in an increase in IL-1β secretion and pro-IL-1β and pro-caspase-1 cleavage

To eliminate possible overexpression artifacts, we used human monocytic THP-1 cells that endogenously express NALP3 and inflammasome components and generated stable NLRC3 knockdown THP-1 cell lines by using three different shRNAs (shD6, shD8, and shD9) (Fig. 2A). We obtained a significant decrease in NLRC3 levels with shD9- and shD6-injected cells, whereas no change was observed with the shD8 cell line (Fig. 2A). When stimulated with MSU, the IL-1β secretion observed correlated with the NLRC3 levels (Fig. 2B; 1118.13 ± 60.7 pg/ml for shcont versus 1067.11 ± 110.4 pg/ml for shD6, p = 0.45; 9991.68 ± 740.6 pg/ml for shD6, p = 10−7; 11591.68 ± 372.8 pg/ml for shD9, p = 10−7).

Because the shD9 cell line gave the more significant decrease in NLRC3 level, we used it in the rest of our experiments and named it shNLRC3. Similarly, although basal IL-1β secretion was not significantly different between shNLRC3 and shcont cells, stimulation of the NALP3 inflammasome with ATP (Fig. 2C; 6376.7 ± 1473.5 pg/ml for shNLRC3 versus 1746 ± 71.3 pg/ml for shcont, p = 0.0008; supplemental Fig. 1A) or nigericin (Fig. 2D, 14253.4 ± 2239.9 pg/ml for shNLRC3 versus 3760.1 ± 182.4 pg/ml for shcont, p = 0.022) resulted in higher IL-1β release in cells where NLRC3 was knocked down. Moreover, an increase in pro-IL-1β cleavage in the supernatant (Fig. 2E and supplemental Fig. 1B) and higher pro-caspase-1 processing (Fig. 2F) were observed in the shNLRC3 line compared with shcont in response to nigericin treatment. Also, the shNLRC3 line induced higher cell death compared with its control shcont counterpart when stimulated with nigericin (Fig. 2G; 42.2 ± 3.3% versus 18.9 ± 2.3% of cell death, p = 10−3, and supplemental Fig. 2). Thus, we concluded that the endogenous NLRC3 protein suppresses the activation of the NALP3 inflammasome induced by different types of ligand and the resulting pyroptotic cell death.

NLRC3 is also an inhibitor of the NLRC4 (IPAF) inflammasome

To determine whether the inhibitory effect of NLRC3 is specific to the NALP3 complex or whether it could also modulate the activity of other inflammasomes, the NLRC4 (or IPAF) inflammasome was stimulated by live P. aeruginosa infection. Knockdown of the NLRC3 protein in THP-1 cells significantly
increased IL-1β secretion in response to *P. aeruginosa* infection compared with NLRC3-expressing cells (Fig. 2H, 9493.9 ± 1256.8 pg/ml for shNLRC3 *versus* 3099.96 ± 1256.7 pg/ml for shcont, *p* = 0.04). Because NLRC3 inhibits both the NALP3 and NLRC4 inflammasomes, we concluded that it may be acting downstream of the receptor proteins.
**NLRC3 inhibits NALP3 inflammasome-induced inflammation**

**NLRC3 does not regulate the protein levels of the inflammasome components**

NLRC3 was shown to inhibit the NFκB pathway by inducing the ubiquitination of TRAF6 and targeting it for proteasomal degradation (26). We investigated whether NLRC3 exerts its inhibitory effect through induction of proteasomal degradation of the inflammasome components by co-transfecting constant NALP3, ASC, and pro-IL-1β concentrations and increasing the amount of NLRC3. No difference was observed in transfected NALP3, ASC, or pro-IL-1β protein levels at different NLRC3 concentrations (Fig. 3, A–C), suggesting that NLRC3 inhibits the inflammasome by a mechanism independent of protein degradation or synthesis.

**NLRC3 interacts endogenously with pro-caspase-1 via its CARD and with ASC but not with NALP3**

We have shown previously that NLRC3 co-localizes and interacts with ASC and caspase-1 when overexpressed in HEK293FT cells (28). Here we investigated whether NLRC3 could interact with NALP3. When the two proteins were overexpressed in HEK293FT cells, immunoprecipitation of either NALP3 (Fig. 3D) or NLRC3 (Fig. 3E) did not pull down...
NLRC3 or NALP3, respectively. Furthermore, the endogenous NLRC3 and NALP3 proteins did not interact with each other in any of the untreated or nigericin- and MSU treated THP-1 cells (Fig. 3F).

As a next step, to verify that the interactions that were seen previously between NLRC3 and ASC or caspase-1 are also occurring physiologically, the endogenous proteins were immunoprecipitated from THP-1 cells. Endogenous NLRC3 interacted with both endogenous ASC (Fig. 3, F and G) and pro-caspase-1 (Fig. 3H). In this study, we used a commercial anti-caspase-1 antibody that is directed against the p10 subunit of caspase-1. Although immunoprecipitation with the anti-caspase-1 p10 antibody pulled down both pro-caspase-1 and the mature, CARD-lacking caspase-1 p20 peptide, the anti-NLRC3 antibody immunoprecipitated only the CARD-containing pro form of caspase-1 (Fig. 3H). Thus, we concluded that NLRC3 interacts with the CARD of caspase-1.

**NLRC3 prevents the assembly of ASC specks through its CARD and LRR domain**

Another informative way of measuring inflammasome activity is to count the number of ASC specks that are formed. To characterize which domain of NLRC3 disrupts ASC speck formation, we cloned its NLRC3CARD (aa 1–60), anti-caspase-1 antibody, and anti-rabbit IgG antibody.
NLRC3 inhibits NALP3 inflammasome-induced inflammation

Although transfection of NALP3 into HEK293FT-ASC-EGFP cells triggered ASC speck assembly (Figs. 4 and 6), full-length NLRC3 (NLRC3FL) itself or its domains had no effect on ASC speck formation on their own (data not shown). However, when NALP3 was co-expressed with NLRC3FL, NLRC3CARD, NLRC3LRR, NLRC3CARD/NACHT, and NLRC3NACHT/LRR, the number of ASC specks formed was significantly lower than the number of specks formed in the presence of NALP3 alone (Fig. 4, C and D). Thus, we concluded that the CARD and LRR domain of NLRC3 were responsible for the disruption of the NALP3-induced complex assembly and that the central NACHT domain had no effect.

Figure 4. NLRC3 prevents the assembly of ASC specks through its CARD and LRR domain. A. NLRC3 protein structure. Different domains and amino acid numbers are shown. B. Western blot result showing the expression of Myc-tagged, full-length NLRC3 and separate domains. Anti-Myc antibody was used. C/N, CARD/NACHT; N/L, NACHT/LRR. Predicted molecular weights: FL, 117 kDa; NACHT, 63 kDa; LRR, 49 kDa; CARD/NACHT, 69 kDa; NACHT/LRR, 110 kDa. C, representative pictures of three sets of independent experiments of the effect of the domains of NLRC3 on ASC speck formation induced by NALP3. D, quantification of ASC specks formed in the presence of the domains of NLRC3 (the p values shown are the indicated condition compared with the NALP3 + Myc only condition, Student’s t test).
NLRC3 co-localizes with diffused ASC proteins and competes with ASC for pro-caspase-1 binding

To confirm that NLRC3 co-localizes with ASC endogenously, we stained PMA-differentiated and nigericin-treated THP-1 macrophages with anti-NLRC3 and anti-ASC antibodies. We found that NLRC3 and diffuse ASC stainings overlapped each other in the cytosol; however, an NLRC3 signal was not observed on ASC specks (Fig. 5A). Furthermore, we could not detect the NLRC3 protein by Western blotting of the lysate containing ASC specks isolated from ASC- and NLRC3-co-transfected cells (Fig. 5B). Taken together, these results demonstrate that NLRC3 interacts with diffused ASC proteins but is not embedded into ASC specks after inflammasome activation.

Because NLRC3 interacts with both ASC and pro-caspase-1, we determined whether NLRC3 might affect the interaction between these two proteins. Although ASC and pro-caspase-1 interacted with each other when they were overexpressed in HEK293FT cells, addition of NLRC3 resulted in a weaker interaction between ASC and pro-caspase-1 in both samples immunoprecipitated with anti-ASC (Fig. 5D) or anti-caspase-1 (Fig. 5E) antibodies. Moreover, increasing the concentration of NLRC3 by keeping a constant amount of ASC and pro-caspase-1 proteins (Fig. 5C) decreased the interaction between ASC and pro-caspase-1 even more. Thus, NLRC3 may exert its inhibitory effect before complex formation by sequestering the pro-caspase-1 proteins and by
blocking the assembly of pro-caspase-1 and ASC required for inflammasome activity.

The CARD of NLRC3 is necessary and sufficient to inhibit inflammasome activation triggered by NALP3 mutants associated with autoinflammatory syndromes

Because mutations in the NALP3 gene are known to induce the constitutive activation of the NALP3 inflammasome, we tested whether full-length NLRC3 and NLRC3CARD are able to suppress this aberrant inflammatory response. We found that both full-length–NLRC3 (269.2 ± 5.8 pg/ml versus 216 ± 13.7 pg/ml for WT NALP3, p = 0.0004; 841.4 ± 26.6 pg/ml versus 311.2 ± 9.2 pg/ml for p.R260W NALP3, p = 10⁻⁸; 1150 ± 47.3 pg/ml versus 195.1 ± 32.1 pg/ml for p.D303N NALP3, p = 10⁻⁷) and NLRC3CARD (109.3 ± 21.8 pg/ml for WT NALP3, p = 10⁻⁸; 122 ± 14.8 pg/ml for p.R260W NALP3, p = 10⁻⁷; 45.2 ± 13.3 pg/ml for p.D303N NALP3, p = 10⁻⁶; all compared with the “no NLRC3” conditions) inhibit IL-1β secretion induced by the ectopically assembled inflammasome complex in HEK293FT cells, and NLRC3CARD had an even more significant effect than the full-length protein (Fig. 6A, p = 0.0002 for WT NALP3, p = 10⁻⁷ for NALP3 p.R260W, and p = 0.0001 for NALP3 p.D303N). Furthermore, NLRC3FL and NLRC3CARD also impaired the ASC speck formation triggered by WT and NALP3 p.R260W proteins (Fig. 6, B and C). On the other hand, no effect was observed on the number of ASC specks formed by NALP3 p.D303N proteins, probably because the concentration of transfected NLRC3 was not high enough to block the excessive effect of the NALP3 p.D303N mutant. These data demonstrate that the CARD of NLRC3 is able and sufficient to repress the NALP3 inflammasome activity under normal or pathologic conditions.

Discussion

We investigated, in this paper, the potential effect of the NLRC3 protein on the activation of the NALP3 inflammasome using human THP-1 monocytes and HEK293FT cells when we had to ectopically express an exogenous protein. We found that NLRC3 decreases the number of ASC specks formed, the maturation of pro-IL-1β and pro-caspase-1 proteins, and the secretion of IL-1β in both overexpression and endogenous experimental settings. The suppressive effect of NLRC3 on the NALP3 inflammasome in THP-1 cells was stimulant-independent because complex activation in response to all ligands used (ATP, nigericin, and MSU) was affected by NLRC3.

Moreover, the CARD of NLRC3 was necessary to exert this inhibition. NLRC3 had no effect on protein levels, and its suppressive effect was independent of its role on the NFκB pathway because, with the use of HEK293FT cells, overexpression of these proteins bypassed transcriptional regulation of the inflammasome components. Another advantage of HEK293FT cells that do not express the ASC adaptor protein at all and negligible levels of the other inflammasome components was the possibility to introduce mutant NALP3 proteins or different NLRC3 domains without possible interference of the WT NALP3 or full-length NLRC3 proteins, respectively.

Recruitment of pro-caspase-1 proteins by the ASC adaptor to foci is a very critical step in the activation of inflammasomes. The CARD–CARD interaction between ASC and pro-caspase-1 was required for complex formation because mutagenesis of some residues in these domains abolished ASC/pro-caspase-1 binding and inflammasome activation (29). Similarly, the self-oligomerization of the CARD of caspase-1 was also shown to prevent its interaction with ASC (30). Here we showed that the presence of NLRC3, which also contains a CARD, decreases the interaction between ASC and pro-caspase-1. The absence of an NLRC3 and NALP3 interaction showed that the presence of NLRC3 and NALRC3CARD mutants in the presence or absence of NLRC3 and NALRC3CARD. Shown are quantification of ASC specks (B) and representative images of three sets of independent experiments (C). Samples were compared with Student’s t test.
caspase-1 assembly through its CARD (31). More recently, an antibody generated against the CARD of ASC was sufficient to inhibit inflammasome activation (32), again suggesting how important the interaction of ASC and caspase-1 through their CARD domain is.

Overall, we propose in this paper that, besides its previously defined suppressive role in the NFκB pathway, NLRC3 is also a novel inhibitor of activation of the NALP3 and NLRC4 inflammasomes through disruption of ASC speck assembly by competing with the ASC protein for binding to the CARD of pro-caspase-1.

**Experimental procedures**

**Plasmids used in this study**

The pcDNA3-ASC, pcDNA3-FLAG-pro-caspase-1, pro-IL-1β-ires-EGFP, pcDNA3-FLAG-WT_NALP3, pcDNA3-FLAG-R260W_NALP3, and pcDNA3-FLAG-D303N_NALP3 plasmids were kind gifts from Prof. Gabriel Nunez (University of Michigan). Full-length NLRC3 was cloned in our laboratory as described previously (28). The domains of NLRC3 were amplified from the pcDNA3-Myc-NLRC3 template with NLRC3CARD (aa 1–60) ForwCARD-XbaI (TAATGCTAGAAGGAGPGGCTGCG) and RevCARD-Stop-NotI (TATGCGGCCGCTCAATGCACTGCGT). NLRC3NACHT (aa 61–1065) ForwNACHT-XbaI (GGC-GGGCTAGCTCAAGGATACAGGAG) and RevNACHT-Stop-NotI (TAAATGGCGCCTGCTGCGTACACAGG) were inserted into the pcDNA3-FLAG vector. For the generation of NLRC3-D9, NLRC3-D10, and mNLRC3, NLRC3 was amplified from the pcDNA3-Myc-NLRC3 template with ForwLRR-XbaI (ATGGTCTAGTGAGGCCAAC-CTGTCC) and RevLRR-Stop-NotI primers, digested with the indicated enzymes, and ligated into XbaI-PspOMI-digested and purified empty pcDNA3-Myc vector. To generate the pLenti-CMV-Blst-NLRC3 vector, full-length NLRC3 was extracted from the pET30a-NLRC3 vector by BglII and RevEcoRI digestions and inserted in a 3:1 ratio into the BamHI-XhoI-digested and purified empty pcDNA3-Myc vector. Each treatment was performed in duplicate or triplicate. Supernatants were harvested and cleared from cells, and IL-1β levels were measured by ELISA.

**Generation of the NLRC3 knockdown and NLRC3-overexpressing stable THP-1 cell lines**

Viruses were produced in HEK293FT cells by transfection of pLKO.1-shNLRC3 and control pLKO.1-shGFP vectors (kindly provided by Assist. Prof. Ömer Yılmaz, Broad Institute, Massachusetts Institute of Technology, Boston, MA) or newly generated pLenti-CMV-Blst-NLRC3 (OvNLRC3) vectors and their control pLenti-CMV-Blst (named OvCont) together with the helper plasmids pMD2G and psPAX2. THP-1 cells were spinoculated for 30 min at 32°C, incubated with the virus for 4 h at 37°C and 5% CO2, and selected with 1 μg/ml puromycin or 1 μg/ml blasticidin. Four different shRNAs targeting different parts of NLRC3 cloned into the pLKO.1 vector (shNLRC3-D6 (TRCN000168401), shNLRC3-D8 (TRCN000168587), shNLRC3-D9 (TRCN000168194), and mouse NLRC3-specific shmNLRC3-D7 (TRCN000168383)) were used to confirm the reproducibility of the NLRC3 knockdown phenotype.

**Activation of the NLPC3 and IPAF/NLRC4 inflammasomes in THP-1 cells**

106 shcont or shNLRC3 or OvNLRC3 and OvControl THP-1 stable lines were seeded into a 6-well plate and differentiated into macrophages with 3 h of 0.5 μM PMA treatment. The next day, cells were primed for 2 or 4 h with 100 ng/ml LPS and treated with 20 μM nigericin, 5 mM ATP, or 150 μg/ml MSU for 4 or 6 h, respectively, for NALP3 inflammasome activation and treated with 75 μl/ml of P. aeruginosa for 4 h for IPAF/NLRC4 inflammasome activation. Supernatants were harvested and cleared from cells, and IL-1β levels were measured by ELISA.

**Measurement of secreted IL-1β levels by ELISA**

IL-1β levels were determined in 1 ml of cell supernatant by using the R&D Systems human IL-1β IL-1F kit according to the protocol of the manufacturer. Each treatment was performed in duplicate or triplicate, and the supernatants were measured in duplicate. Significance between samples was determined by two-tailed Student’s t test.

**Co-immunoprecipitation of the endogenous and overexpressed inflammasome components**

Commercially available anti-NLRC3 (Abcam, ab77817), anti-caspase-1 (Santa Cruz Biotechnology, sc-515), anti-ASC hybridoma supernatant (a kind gift from Assist. Prof. Junya Masumoto, Ehime University, Ehime, Japan), and anti-NALP3 (Abcam, ab17267) antibodies were used. For co-immunoprecipitation in the overexpression system, anti-Myc (Cell Signaling Technology, 2272) and anti-FLAG (Cell Signaling Technology, 2368) antibodies were used.

**ASC speck formation assay**

The HEK293FT-ASC-EGFP stable cell lines generated in our laboratory were transfected with NALP3, full-length NLRC3, or the different domains of NLRC3 in a 6-well plate with 500 ng of NALP3, 500 ng of NLRC3, or 500 ng of the different domains of NLRC3 (Fig. 4) or 1 μg of WT NALP3, NALP3 pr260W, or NALP3 pD303N and 1 μg of NLRC3 (Fig. 6). An equal amount
NLRC3 inhibits NALP3 inflammasome-induced inflammation

of DNA was transfected by using the pcDNA3-Myc empty vector. The number of ASC specks was counted 24 or 48 h after transfection under a fluorescence microscope. Each condition was transfected into two wells, and eight randomly chosen fields were counted for each well.

Isolation of the ASC specks

ASC specks were isolated from four 100-mm plates of 5 × 10^6 HEK293FT cells each and transfected with 4 μg of mCherry-ASC plasmid. 24 h after transfection, samples were sonicated, vortexed until filaments were formed, and spun down at 200 × g for 1 h. The pellet was dissolved in 30 ml of PBS, passed through a 5-μm filter, and spun down at 2400 × g for 1 h. The final pellet containing ASC specks was dissolved in 500 μl of PBS. The purity of isolated ASC specks was verified under the microscope and by Western blotting.

Competition assay for the binding of NLRC3 to its interaction partners

5 × 10^6 HEK293FT cells were transfected with constant pcDNA3-ASC (2 μg) and pcDNA3-FLAG-pro-caspase-1 (2 μg) and increasing concentrations of pcDNA3-Myc-NLRC3 (1, 2, and 3 μg). Cells were harvested 24 h after transfection, and immunoprecipitation was performed.

LDH assay

An LDH cytotoxicity detection kit from Biovision was used according to the protocol of the manufacturer. The percentage of cell death was determined with the formula (OD sample – OD LDH - )/(OD LDH + – OD LDH - ). Untreated controls were used as LDH - samples and Triton X–treated control cells as LDH + samples.

Author contributions—E. E. designed and performed the experiments and wrote the manuscript. M. B. contributed to the realization of some experiments. N. O. designed the experiments, wrote the manuscript, and provided financial resources.

Acknowledgments—We thank the persons cited in the text for generously sharing the indicated materials with us. We also thank Dr. Stefan A. Köstler for taking the confocal images.

References

1. Martinon, F., Burns, K., and Tschopp, J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol. Cell 10, 417–426.
2. Schroder, K., and Tschopp, J. (2010) The inflammasomes. Cell 140, 821–832.
3. Srivivasulu, S. M., Poyet, J. L., Razmara, M., Datta, P., Zhang, Z., and Alnemri, E. S. (2002) The PY Rin-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277, 21119–21122.
4. Fernandes-Alnemri, T., Wu, J., Yu, W. D., Datta, P., Miller, B., Jankowski, W., Rosenberg, S., Zhang, J., and Alnemri, E. S. (2007) The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590–1604.
5. Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O’Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., and Dixit, V. M. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232.
6. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241.
7. Sutterwala, F. S., Mijares, L. A., Li, L., Ogura, Y., Kazmierczak, B. I., and Flavell, R. A. (2007) Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRB inflammasome. J. Exp. Med. 204, 3235–3245.
8. Bauerfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Mons, B. G., Fitzgerald, K. A., Hornung, V., and Latz, E. (2009) Cutting edge: NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787–791.
9. Pétrilli, V., Papin, S., Dostert, C., Mayor, A., Martinon, F., and Tschopp, J. (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583–1589.
10. Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendran, T. M., and Núñez, G. (2013) K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142–1153.
11. Hornung, V., Bauerfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., and Latz, E. (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847–856.
12. Zhou, R., Yazdi, A. S., Menu, P., and Tschopp, J. (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225.
13. Hoffman, H. M., Mueller, J. L., Brodie, D. H., Wanderer, A. A., and Kolodner, R. D. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29, 301–305.
14. Yu, J. W., Wu, J., Zhang, Z., Datta, P., Ibrahimi, I., Taniguchi, S., Sagara, J., Fernandes-Alnemri, T., and Alnemri, E. S. (2006) Cryopyrin and pyrin activate caspase-1, but not NF-kB, via ASC oligomerization. Cell Death Differ. 13, 236–249.
15. Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martinez, C. M., Amores-Iniesta, J., Compan, V., Barberá-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., Buján, S., Couillin, I., Brough, D., Arosteegui, I. L., and Pelegri, P. (2014) The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 15, 738–748.
16. Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., and Tschopp, J. (2004) NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319–325.
17. Dowds, T. A., Masumoto, J., Zhu, L., Inohara, N., and Núñez, G. (2004) Cryopyrin-induced interleukin 1β secretion in monocytes: enhanced activity of disease-associated mutants and requirement for ASC. J. Biol. Chem. 279, 21924–21928.
18. Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., and Firestein, G. S. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779–1785.
19. Hawkins, P. N., Lachmann, H. J., and McDermott, M. F. (2003) Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583–2584.
20. Bauerfeind, F., Rieger, A., Schildberg, F. A., Knolle, P. A., Schmid-Burgk, J. L., and Hornung, V. (2012) NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 189, 4175–4181.
21. Coll, R. C., Robertson, A. A., Chae, J. I., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., Croker, D. E., Butler, M. S., Haneklaus, M., Sutton, C. E., Núñez, G., et al. (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255.
22. Stack, J. H., Beaumont, K., Larsen, P. D., Straley, K. S., Henkel, G. W., Randle, J. C., and Hoffman, H. M. (2005) IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 175, 2630–2634.
23. Xia, X., Cui, J., Wang, H. Y., Zhu, L., Matsueda, S., Wang, Q., Yang, X., Hong, J., Songyang, Z., Chen, Z. J., and Wang, R. F. (2011) NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. *Immunity* 34, 843–853
24. Tong, Y., Cui, J., Li, Q., Zou, J., Wang, H. Y., and Wang, R. F. (2012) Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. *Cell Res.* 22, 822–835
25. Conti, B. J., Davis, B. K., Zhang, J., O’connor, W., Jr, Williams, K. L., and Ting, J. P. (2005) CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. *J. Biol. Chem.* 280, 18375–18385
26. Schneider, M., Zimmermann, A. G., Roberts, R. A., Zhang, L., Swanson, K. V., Wen, H., Davis, B. K., Allen, I. C., Holl, E. K., Ye, Z., Rahman, A. H., Conti, B. J., Eitas, T. K., Koller, B. H., and Ting, J. P. (2012) The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. *Nat. Immunol.* 13, 823–831
27. Zhang, L., Mo, J., Swanson, K. V., Wen, H., Petrucelli, A., Gregory, S. M., Zhang, Z., Schneider, M., Jiang, Y., Fitzgerald, K. A., Ouyang, S., Liu, Z. J., Damania, B., Shu, H. B., Duncan, J. A., et al. (2014) NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. *Immunity* 40, 329–341
28. Gültekin, Y., Eren, E., and Özören, N. (2015) Overexpressed NLRC3 acts as an anti-inflammatory cytosolic protein. *J. Innate Immun.* 7, 25–36
29. Proell, M., Gerlic, M., Mace, P. D., Reed, J. C., and Riedl, S. J. (2013) The CARD plays a critical role in ASC foci formation and inflammasome signaling. *Biochem. J.* 449, 613–621
30. Narayanan, K. B., and Park, H. H. (2015) Purification and analysis of the interactions of caspase-1 and ASC for assembly of the inflammasome. *Appl. Biochem. Biotechnol.* 175, 2883–2894
31. Sarkar, A., Duncan, M., Hart, J., Hertlein, E., Guttridge, D. C., and Wewers, M. D. (2006) ASC directs NF-κB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions. *J. Immunol.* 176, 4979–4986
32. Schmidt, F. I., Lu, A., Chen, J. W., Ruan, J., Tang, C., Wu, H., and Ploegh, H. L. (2016) A single domain antibody fragment that recognizes the adaptor ASC defines the role of ASC domains in inflammasome assembly. *J. Exp. Med.* 213, 771–790

**NLRC3 inhibits NALP3 inflammasome-induced inflammation**